financetom
Business
financetom
/
Business
/
Tesla's Valuation Increasingly Difficult to Justify Amid AI Enthusiasm, Core Auto Business Deterioration, UBS Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Tesla's Valuation Increasingly Difficult to Justify Amid AI Enthusiasm, Core Auto Business Deterioration, UBS Says
Jul 12, 2024 9:47 AM

12:16 PM EDT, 07/12/2024 (MT Newswires) -- Tesla's (TSLA) valuation is increasingly difficult to justify amid a lack of visibility and the risk that growth opportunities including in artificial intelligence materialize on a longer time horizon, UBS Securities said in a note Friday.

Tesla has always carried a premium for its future growth initiatives, but recent enthusiasm around artificial intelligence has widened this premium, making it challenging to value accurately, according to the note.

"While Tesla is investing heavily in artificial intelligence, the technology is making progress, investment is costly, the pace of improvement may slow and the payoff is long-dated," UBS added. "If market enthusiasm for artificial intelligence diminishes, this may impact Tesla's multiple."

Tesla's non-auto contributions, which are becoming increasingly important as expectations for the company's core Auto business deteriorate, to its stock price are high, indicating a good opportunity to sell as the stock tends to trend downwards "when other becomes a larger contributor to price."

UBS said it could be wrong if Tesla's stock price disconnects from fundamentals, Q2 results exceed expectations or positive surprises on "robo-taxi" day boost momentum.

The firm downgraded its rating on Tesla to sell from neutral and increased the price target to $197 from $147.

Shares of Tesla were up about 4% in recent trading.

Price: 250.19, Change: +9.16, Percent Change: +3.80

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cassava Shares Are Down Over 30%: Here's Why
Cassava Shares Are Down Over 30%: Here's Why
Jun 28, 2024
Cassava Sciences, Inc. ( SAVA ) shares are trading significantly lower on Friday following the indictment of Hoau-Yan Wang, a tenured medical professor and advisor to the company, by a federal grand jury. What’s Going On: Wang has been accused of fabricating scientific data in grant applications to the U.S. National Institutes of Health (NIH), resulting in the misappropriation of...
Intercontinental Exchange Insider Sold Shares Worth $259,381, According to a Recent SEC Filing
Intercontinental Exchange Insider Sold Shares Worth $259,381, According to a Recent SEC Filing
Jun 28, 2024
04:15 PM EDT, 06/28/2024 (MT Newswires) -- Andrew J Surdykowski, General Counsel, on June 26, 2024, sold 1,898 shares in Intercontinental Exchange ( ICE ) for $259,381. Following the Form 4 filing with the SEC, Surdykowski has control over a total of 46,815 shares of the company, with 46,815 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1571949/000095017024079022/xslF345X03/ownership.xml Price: 136.89, Change: +0.06, Percent...
Addus HomeCare Closes $176 Million Underwritten Public Offering
Addus HomeCare Closes $176 Million Underwritten Public Offering
Jun 28, 2024
04:11 PM EDT, 06/28/2024 (MT Newswires) -- Addus HomeCare ( ADUS ) said Friday it raised $176 million from an underwritten public offering of shares. The company sold over 1.7 million shares in the offering at $108 per share, including full exercise of the underwriters' option to buy up to 225,000 shares, Addus added. Addus said it plans to use...
Why Are Carisma Therapeutics Shares Surging Friday?
Why Are Carisma Therapeutics Shares Surging Friday?
Jun 28, 2024
Carisma Therapeutics Inc. ( CARM ) shares are trading higher on Friday following the company’s announcement of a significant development in its collaboration with Moderna. What To Know: Carisma has nominated its first in vivo CAR-M development candidate targeting Glypican-3 (GPC3) for the treatment of solid tumors, including hepatocellular carcinoma (HCC). This milestone has triggered a $2 million payment to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved